PureTech Health PLC

NASDAQ PRTC

Data sourced from

and

Daily

Download Data

PureTech Health PLC Price to Sales Ratio (P/S) on June 03, 2024: 245.21

PureTech Health PLC Price to Sales Ratio (P/S) is 245.21 on June 03, 2024, a NA change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.

PureTech Health PLC 52-week high Price to Sales Ratio (P/S) is 260.88 on May 31, 2024, which is 6.39% above the current Price to Sales Ratio (P/S).
PureTech Health PLC 52-week low Price to Sales Ratio (P/S) is 38.62 on February 21, 2024, which is -84.25% below the current Price to Sales Ratio (P/S).
PureTech Health PLC average Price to Sales Ratio (P/S) for the last 52 weeks is 99.77.

NASDAQ: PRTC

PureTech Health PLC

CEO	Ms. Daphne Zohar
IPO Date	Nov. 16, 2020
Location	United States
Headquarters	6 Tide Street, Boston, MA, United States, 02210
Employees	90
Sector	Healthcare
Industry	Biotechnology

Description

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Key trends